SEC sub­poe­naes Bio­Marin in dris­apersen probe; Job hunt­ing? The FDA has hun­dreds of open po­si­tions

Bio­Marin $BM­RN has more headaches to con­tend with on its Duchenne mus­cu­lar dy­s­tro­phy drug dris­apersen. The com­pa­ny says in its new­ly post­ed quar­ter­ly re­port with the SEC that it is co­op­er­at­ing with an SEC in­ves­ti­ga­tion in­to the drug, which was re­ject­ed by the FDA and the EMA. Bio­Marin has been re­think­ing its de­ci­sion to bury the drug, pon­der­ing an ap­peal of the FDA’s po­si­tion. Its state­ment on the SEC: In Au­gust 2016, we re­ceived a sub­poe­na from the staff of the SEC re­quest­ing that we pro­duce doc­u­ments in con­nec­tion with a non-pub­lic, fact-find­ing in­quiry re­lat­ed to our for­mer dris­apersen pro­gram. The let­ter en­clos­ing the sub­poe­na states that the in­ves­ti­ga­tion and the sub­poe­na do not mean that the Com­pa­ny or any­one else has bro­ken the law, or that the SEC has a neg­a­tive opin­ion of any per­son, en­ti­ty or se­cu­ri­ty. We in­tend to co­op­er­ate ful­ly with the SEC in this mat­ter. We are not able to pre­dict whether any pro­ceed­ing may be in­sti­tut­ed in con­nec­tion with the sub­poe­na, or the out­come of any pro­ceed­ing that may be in­sti­tut­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER